Form D · Biotechnology
Shuttle Pharmaceuticals, Inc.
Rockville, MD · CIK 0001685462
Offering snapshot reported Sep 26, 2016 · SEC filing
- Reported sold
- $120K Offering amount: $120K
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $3K Reported outside-investor minimum
- First sale
- Sep 12, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 26, 2016 | Initial | $120,250 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 04
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-271270
Convertible Debt
Source: Form D, filed Sep 26, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Milton Brown | Director, Executive |
| Anthony Dritschilo | Director, Executive |
| Peter Dritschilo | Executive |
| Mira Jung | Director, Executive |
| Gene Jung | Executive |
| Theodore Phillips | Executive |
| Michael Starkweather | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Research Court Suite 450
Rockville, MD, 20850
Rockville, MD, 20850